Congenital erythropoietic porphyria (CEP), an inborn error of heme biosynthesis, results from the deficient activity of uroporphyrinogen III synthase (URO-synthase). This autosomal recessive disorder is heterogeneous; patients with severe disease are often transfusion dependent, while milder patients primarily have cutaneous involvement. To investigate this phenotypic heterogeneity, exonic point mutations in the URO-synthase gene were identified in unrelated CEP patients. Four missense mutations were identified: (a) an A to G transition of nucleotide (nt) 184 that predicted a Thr to Ala substitution at residue 62 (designated T62A); (b) a C to T transition of nt 197 that encoded an Ala to Val replacement at residue 66 (A66V); (c) a T to C transition of nt 217 that predicted a Cys to Arg substitution at residue 73 (C73R); and (d) a C to T transition of nt 683 that resulted in a Thr to Met replacement at residue 228 (T228M). In addition, a G to A transition of nt 27 that did not change the encoded amino acid (A9A) was detected in an African patient. The T62A, C73R, and T228M alleles did not express detectable enzymatic activity, while the A66V allele expressed residual, but unstable activity. The C73R allele was present in eight of 21 unrelated CEP patients (21% of CEP alleles). In three patients, identification of both alleles permitted genotypephenotype correlations; the A66V/C73R, T228M/C73R, and C73R/C73R genotypes had mild, moderately severe, and severe disease, respectively. These findings provide the first genotype-phenotype correlations and permit molecular heterozygote detection in this inherited porphyria. (J. Clin. Invest.
Introduction
Congenital erythropoietic porphyria (CEP),' also known as Gunther's disease, is an inborn error of heme biosynthesis that results from the markedly deficient activity of the fourth en-zyme of the heme biosynthetic pathway, uroporphyrinogen III synthase [URO-synthase; also designated hydroxymethylbilane hydro-lyase (cyclizing); EC 4.2.1.751 (1, 2) . This enzyme normally catalyzes the rapid cyclization of the linear tetrapyrrole, hydroxymethylbilane (HMB), to form the uroporphyrinogen III isomer, the physiologic precursor of heme (3, 4) . In patients with this autosomal recessive disorder, the enzymatic defect leads to the accumulation ofHMB which is nonenzymatically cyclized to the uroporphyrinogen I isomer and then oxidized to uroporphyrin I (URO I), a nonphysiologic and pathogenic compound (1) . The accumulated URO I in erythrocytes leads to hemolysis, and the released porphyrin isomer is deposited in tissues and bones and excreted in the urine and feces.
URO I is a photocatalytic compound, and exposure of the skin to sunlight, other forms of ultraviolet light, or trauma results in blistering and vesicle formation (5) . Ruptured vesicles are prone to secondary infection leading to cutaneous scarring and deformities, particularly of the hands and face. Severely affected patients are transfusion-dependent, and have secondary hypersplenism and disfiguring cutaneous involvement, whereas mildly affected patients may have only cutaneous manifestations (6) . Later-onset adult patients with mild disease symptoms also have been described (e.g., 7, 8) .
Diagnosis ofCEP patients can be reliably made by the demonstration of deficient URO-synthase activity in erythrocytes or cultured cells (9-1 1) . Affected individuals are not totally deficient in URO-synthase activity since they must have sufficient residual activity to synthesize uroporphyrinogen III for the production of heme. Presumably, the amount of residual URO-synthase activity primarily determines the severity ofthe disease; however, at present it is not possible to biochemically predict disease severity (9) . In addition, it is difficult to enzymatically identify heterozygous carriers ofthe disease gene due to the overlap of low-normal and high heterozygous values (9) .
Human URO-synthase has been purified to homogeneity from erythrocytes, and shown to be a monomeric protein with an apparent molecular weight of 29.5 kD (12) . Recently, the full-length cDNA encoding the human URO-synthase polypeptide of 265 amino acids was isolated, sequenced, and expressed in Escherichia coli (13) . Using the cDNA as a probe, a single URO-synthase gene has been regionally assigned to a narrow region of chromosome lOq25.3 --q26.3 (14) . Genomic clones have been obtained, and exon-intron junctions in the -60 kb URO-synthase gene have been determined (Warner, C. A., S-F Tsai, and R. J. Desnick, unpublished results).
The availability of the URO-synthase cDNA provided the opportunity to investigate the molecular nature of the phenotypic variability in unrelated patients with CEP. While these studies were in progress, Deybach et al. reported two putative mutations (P53L and C73R) in two severely affected patients (15). In this communication, five exonic mutations (designated T62A, A66V, C73R, T228M, and a silent base substitution, A9A) were identified in unrelated CEP patients using reverse transcription and amplification ofthe URO-synthase message, and by analysis of the first four coding exons by the single strand conformation polymorphism (SSCP) technique. Each missense mutation was confirmed by expression studies. Of interest, the A66V allele expressed residual enzymatic activity, consistent with the proband's mild phenotype. In contrast, little, if any, URO-synthase activity was expressed by the other mutant alleles. In several patients, the identification and expression of both mutant alleles permitted the first genotypephenotype correlations in this porphyria.
Methods
Patient specimens. Peripheral blood samples were collected from 21 unrelated CEP patients and their family members with informed consent. Lymphoid cell lines were established using cyclosporin A and Epstein-Barr virus as previously described ( 16) . Cells were maintained by standard procedures in RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin, and 1 mg/ml of streptomycin (Gibco Laboratories, Grand Island, NY).
cDNA amplification and sequencing of mutant URO-synthase alleles. Total RNA was isolated from cultured lymphoblasts using standard techniques (17) . First-strand cDNA was reverse transcribed from -5 ug of total RNA, using a cDNA synthesis kit according to the manufacturer's instructions (Bethesda Research Laboratories, Gaithersburg, MD). The cDNA (-10% of the total reaction) was amplified by the polymerase chain reaction (PCR) with Taq polymerase (PerkinElmer Cetus, Norwalk, CT) essentially as described by Saiki et al. (18) with the following modifications. After an initial denaturation of the RNA-DNA hybrid at 94°C for 5 (Table I) for subcloning into pGEM-4Z and subsequent sequencing as described above.
Allele-specific hybridization of genomic DNA. Any nucleotide change that occurred in more than two subcloned PCR products was considered a candidate mutation and analyzed by dot-blot hybridization of allele-specific oligonucleotides (ASOs) with genomic DNA isolated from peripheral blood leukocytes or lymphoid cells (22, 23) from the patient and appropriate family members. Since the P53L, T62A, A66V, and C73R mutations all occurred within the same URO-synthase exon, genomic DNA was amplified with sense and antisense primer set 3 (Table I) as described above. Amplification for 30 cycles included denaturation at 94°C for I min, annealing at 50°C for 30 s, and extension at 72°C for 30 s. For detection ofthe T228M mutation in genomic DNA, primer set 5 was used (Table I) . Optimal amplification was performed for 30 cycles by denaturation (94°C, 1 min), annealing (55°C, 1.5 min), and extension (72°C, 1.5 min). The standard amplification reaction mixture for all mutations was 3 Ig genomic DNA, I MM of each primer, 200 MM dNTP, 50 mM Tris-HCl pH 9.0, 50 mM NaCl, 10 mM MgCl2, 170 ,g/ml BSA, and 2 U Taq polymerase (Promega Biotec). The PCR product (40 Ml) was denatured in 360 Ml of0.4 M NaOH containing 25 mM EDTA for 5 min, and then 180-Ml aliquots of each were transferred to duplicate Zeta Probe membranes (Bio-Rad Laboratories, Richmond, CA) using a Minifold I dot-blot apparatus (Schleicher and Schuell, Keene, NH). For allele-specific hybridization, the ASOs corresponding to the appropriate normal and mutant sequences (Table II) were end labeled with [_y-32P]ATP (24) , and the radiolabeled ASOs were added to the hybridization solution at a concentration of 106 cpm/ml. Note that the mutation-specific ASO for the T62A lesion required a second base change to reduce non-specific hybridization to the normal sequence. Prehybridizations for 3 h in 6X SSPE (1X SSPE is 0.15 M NaCl, 10 mM NaH2PO4, 1 mM EDTA, pH 7.4), 1OX Denhardt's (I X Denhardt's is 0.1% Ficoll/0. 1% polyvinylpyrrolidone/0. 1% BSA), and overnight hybridizations for the A9A, * URO-synthase intronic and exonic sequences in lower and upper case letters, respectively. EcoRI and KpnI recognition sites in parentheses and brackets, respectively. Underlined nucleotides represent additional non-URO-synthase sequence to facilitate restriction enzyme cleavage. 
* Sense strand sequences are indicated for all oligonucleotides except the mutation-specific T228M ASO which is an antisense sequence.
P53L, T62A, A66V, C73R, and T228M mutations were performed at 47, 40, 50, 55, 50, and 51 'C, respectively. After hybridization, the blots were washed at room temperature for 15 min in 6X SSC (I X SSC is 0.15 M sodium chloride/0.0 15 M sodium citrate, pH 7.0), 0.1 % SDS, and then twice for 30 min each in the same solution at the indicated temperatures for the respective normal or mutation-specific oligonucleotide probe (Table II) . Membranes were exposed to Kodak XAR-5 film with an intensifying screen for -3 h. Prokaryotic expression and characterization of URO-synthase mutations. The normal and mutant URO-synthase alleles were expressed in E. coli using the pKK223-3 vector (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ) as previously described (13) . The AvaIl fragment of the full-length URO-synthase cDNA was blunt-end ligated into the HindIll site ofpKK223-3. This construct was designated pKK-UROS. The pKK-UROS-A66V and pKK-UROS-C73R constructs were synthesized by digesting the respective mutant cDNAs with HindIII, and exchanging the 225-nt fragment as a cassette into the corresponding position in pKK-UROS. Similarly, the pKK-UROS-T62A and pKK-UROS-T228M expression constructs were synthesized using the 586-nt BstXI fragment as the cassette. To construct pKK-UROS-P53L, primers corresponding to nt 139 to 164 (5'-TCTGAGAAGCTTTCT-CATCTTGAAGA-3') and nt 381-357 (5'-TTCTGCAAGCTTTT-CTGCATTTCCA-3'), respectively, were used to amplify a portion of the URO-synthase cDNA. These primers contained the HindIII sites present in the URO-synthase cDNA; the 5' primer had a C to T transition of nt 158 which altered codon 53 to encode a leucine residue. Amplification was performed for 30 cycles with denaturation at 940C for 1 min, annealing at 550C for 1 min, and extension at 720C for 30 s. After phenol/chloroform extraction, ethanol precipitation, and digestion with HindIII, the amplified product was ligated as a cassette into HindIll digested pKK-UROS. After transformation of E. coli, single colonies were isolated and the inserts were sequenced to confirm the presence of the desired mutation. Bacterial growth, IPTG induction, and URO-synthase assays were performed as previously described (13) . For enzyme stability studies, samples from the bacterial lysates, equalized for enzymatic activity, were incubated at 370C in the presence of 0.5 mg/ml of BSA for 60 min. Aliquots were removed at timed intervals, placed on ice, and the URO-synthase activity was determined by the coupled assay (9) .
Results
Identification of the A66 V, C73R, and T228M mutations by cDNA amplification and sequencing. Initial efforts to identify exonic lesions causing CEP focused on two unrelated patients who had about 10% of mean normal erythrocytic URO-synthase activity (9) , and mild to moderate disease manifestations.
Total RNA was isolated from cultured lymphocytes from each proband, reverse-transcribed into cDNA, and then the entire URO-synthase coding region was PCR-amplified. Nucleotide sequencing of eight subcloned PCR products from proband 1, a mildly affected 12-yr-old male, revealed two allelic missense mutations (Fig. 1) . Five ofthe subcloned products had a C to T transition ofnt 197 that predicted an alanine to valine substitution at residue 66 (designated A66V). The other three subclones had amplified products with a T to C transition ofnt 217 which predicted a cysteine to arginine replacement at position 73 (designated C73R). Thus, proband 1 was heteroallelic for the A66V and C73R mutations. Nucleotide sequencing of six subcloned PCR products from proband 2, a moderately severe 15-yr-old male, also revealed two different allelic mutations (Fig. 1) . In three subclones, the amplified products had the C73R mutation, while the other three subclones had a single mutation in a CpG dinucleotide, a C to T transition ofnt 683 that predicted a threonine to methionine replacement in position 228 (designated T228M). In the PCR products from both probands, all other base substitutions occurred in only one or two subclones, and none ofthe amplified products had both mutations, consistent with both probands being heteroallelic for the identified lesions.
Identification ofA9A and T62A mutations by SSCP. Based on the location of the intron/exon boundaries (Warner et al., unpublished results), each of the first four coding exons from 16 unrelated CEP patients was amplified for SSCP analysis. As shown in Fig. 2 , the SSCP profiles for proband 1 (A66V/C73R) and proband 2 (C73R/T228M) revealed mobility shifts in the fourth coding exon (Fig. 2, B, lanes 3 and 4, respectively) . A mobility shift, located between the two major bands, was observed in the profiles of both probands, consistent with detection ofthe C73R lesion. Proband 1 also had a second mobility shift in the top band, consistent with detection of the A66V lesion. In addition, a third mobility shift was detected in the exon 4 profile from proband 3, a mildly affected 16-yr-old Japanese male (Fig. 2, B, Table  III (Fig. 3) .
Analysis of exon 4 (B) revealed that probands 1 and 2 (lanes 4 and 3)
had an additional band between the two major bands found in controls. This shifted band correlated with the presence of the C73R mutation. The top band from proband 1 also was shifted, reflecting the presence of the A66V mutation. Proband 3 (lane 5) had a more rapidly migrating band subsequently identified as a missense mutation, T62A (Fig. 3) . from the proband's genomic DNA and sequenced, an A to G transition ofnt 184 was detected (Fig. 3) that predicted a threonine to alanine substitution (designated T62A).
Examination of the exon 4 SSCP profiles of 14 other unrelated CEP patients revealed the occurrence ofthe C73R mobility shift in six (Table III) . Amplification and sequencing ofthis exon from genomic DNA confirmed the presence ofthe C73R allele in each ofthese CEP patients (data not shown). Similarly, SSCP analyses ofthe first three coding exons from 16 unrelated CEP patients revealed only one other mobility shift. As shown in Fig. 2 (A, lane 6) , a shift was detected in the lower band ofthe exon 2 profile for proband 4, a moderately affected 35-yr-old South African Black female from the Baralong tribe, a subgroup of the Tswana chiefdom. Amplification and sequencing of this exon from genomic DNA of proband 4 identified a mutation in a CpG dinucleotide, a G to A transition of nt 27 (Fig. 3) , which did not predict an amino acid change (designated A9A).
Confirmation ofthe identified mutations by dot-blot analyses. Initial confirmation of the above mutations was made by demonstrating these lesions in genomic DNA from probands 1, 2, 3 and 4, and their respective family members by dot-blot hybridization with ASOs. As shown in Fig. 4 , amplified genomic DNA from proband 1 hybridized to both the normal and mutation-specific ASOs for A66V and C73R, confirming that this patient was heteroallelic for these point mutations. Proband 1 inherited the A66V and C73R alleles from his father and mother, respectively. Similarly, amplified genomic DNA from proband 2 hybridized with the mutation-specific ASOs for C73R (data not shown) and T228M (Fig. 4) , also confirn ing heteroallelism for these two mutations. Proband 2 inherited the C73R and T228M mutations from his mother and father, respectively. Hybridization of amplified exon 4 from proband 3 and his parents with the normal and mutation-specific ASOs for T62A, revealed that the proband was heteroallelic for the mutation, having inherited this base substitution from his mother. Finally, hybridization analysis of genomic DNA from proband 4 revealed that she was heterozygous for the A9A allele. Since her mother did not have this substitution (Fig. 4) , presumably this base change was inherited from her deceased father. Prokaryotic expression ofthe URO-synthase mutations. To further characterize the URO-synthase missense mutations, pKK-UROS expression vectors for each of the mutant alleles were constructed and expressed in E. coli, and the enzymatic activity and stability of the recombinant proteins were determined. Table IV shows the URO-synthase activities of the expressed normal allele and the P53L, T62A, A66V, C73R, and T228M alleles following transformation and IPTG induction. Note that only the A66V mutation had detectable residual activity, while the activities ofthe other missense mutations were less than 1% of the mean level expressed by the normal allele. Fig. 5 compares the stabilities of the expressed A66V and normal URO-synthase proteins when incubated at 37°C. The halflife of the normal enzyme was about 37 min, whereas that for the A66V enzyme was only 14 min, indicating that the mutant protein had about half the stability of the normal enzyme at physiologic temperature.
Occurrence of the URO-synthase mutations in unrelated CEPfamilies. To determine the frequencies ofthe A9A, T62A, A66V, C73R and T228M mutations in unrelated CEP families, genomic DNAs from 19 unrelated CEP patients were analyzed by dot-blot hybridization with mutation-specific ASOs (data not shown). Notably, a severely affected CEP patient (proband 5) who died at five months of age was found to be homoallelic for the C73R mutation; both parents ofproband 5 were heterozygous for the C73R mutation. Five other unrelated patients were heterozygous for the C73R mutation, confirming the results of the exon 4 SSCP analyses described above. Thus, 9 of the 42 CEP alleles examined (21%) had the C73R mutation. In addition, a mildly affected 37-yr-old female was heteroallelic for the T228M mutation; thus, the allele frequency for the T228M mutation was about 5% (2 of 42 alleles studied). Analysis of 70 normal Caucasian, 40 (Fig. 4) . Two of the five base substitutions (A9A and T228M) occurred at CpG dinucleotides, known hot spots for mutations (25, 26) , which occur 13 times in the URO-synthase coding sequence.
These URO-synthase exonic base substitutions were detected by reverse transcription ofmRNA to cDNA, followed by amplification and sequencing of the URO-synthase coding region, or by sequencing amplified regions of genomic DNA in which mobility shifts were observed by SSCP analyses. The latter detection technique was facilitated by the characterization of the intron/exon boundaries of the first four URO-synthase coding exons amplified by the PCR primer sets in Table I . Both mutation detection techniques offer different advantages for the identification of new mutations causing CEP. If cultured lymphoblasts are available from the patient, total RNA can be readily isolated for reverse transcription and amplification of the entire URO-synthase coding region as a single 970-bp product for direct sequencing or sequencing ofindependent subclones. In this way, all exonic base changes can be detected, as shown here for the A66V, C73R, and T228M lesions. Alternatively, knowledge of the intron/exon junctions permits the detection of all exonic base changes as well as splice junction defects by direct sequencing ofamplified genomic DNA. When more 3' intron/exon junctions in the URO-synthase gene are defined, SSCP analyses may identify additional mobility shifts for sequence analyses. It should be noted that certain substitutions will alter the SSCP profile by generating a new band (e.g., T62A and C73R), while other base changes will result in very subtle mobility shifts (e.g., A9A and A66V).
While these studies were in progress, Deybach et al. (15) identified two putative mutations in two severely affected CEP patients; one was homoallelic for the C73R mutation and the other was heteroallelic for C73R and P53L. Neither of these missense mutations was confirmed by expression studies. Thus, four of the five known mutations causing CEP (P53L, T62A, A66V, and C73R) are located within a 20-residue sequence of the URO-synthase polypeptide that is homologous to a region in the human a-globin chain involved in the binding of the D ring of heme (13, 27) , the pyrrole group in HMB which undergoes rearrangement and ring closure catalyzed by URO-synthase. Since all four of these missense mutations are located in coding exon 4, they can be detected readily by amplification of this exon from genomic DNA (using primer set 3, Table I ) and hybridization with ASOs, and/or restriction analyses with FokI (for P53L), and MaeII (C73R), which selectively recognize the mutant or normal sequences.
Prokaryotic expression of the five missense mutations, including P53L, resulted in levels of URO-synthase activity that could not be discriminated from the endogenous E. coli activity, with the notable exception of the A66V allele (Table IV) . The A66V allele expressed a mutant protein with about 15% of normal activity and about half-normal stability when incubated at 37°C (Fig. 5) . Since anti-human URO-synthase antibodies were unavailable, the presence of cross-reactive immunologically detectable enzyme protein was not determined. Therefore, it was not possible to assess whether the mutant alleles which had undetectable residual activity produced enzyme protein.
Of the 21 unrelated CEP patients studied, seven were heteroallelic and one was homoallelic for the C73R mutation. In this sample, the frequency ofthe C73R allele was 21%, indicating that this mutation is a common cause of CEP. When the The other mutant alleles were detected only in the index probands with the exception of T228M, which was identified in a second patient. The P53L mutation was not detected in any of the 21 CEP homozygotes in this study. The identification of these lesions permitted the first genotype-phenotype correlations in this disease. The common C73R allele had little, if any enzymatic activity (Table IV) , and individuals homoallelic for this mutation had severe disease. In addition to the homoallelic C73R patient in this study who expired at five months of age, Deybach et al. also reported a severely affected, transfusion-dependent child who was homoallelic for the C73R mutation (15). It is likely that the cysteine residue in position 73 may be involved in disulfide bond formation, thereby being essential to the secondary structure of the normal enzyme. Subsequent studies of C73R/C73R patients may determine the relative level of cross-reactive immunologic material, thereby determining the relative stability of the mutant enzyme protein.
The phenotypes of individuals who are heteroallelic for the C73R mutation depend on the specific lesion in the other allele (Table III) . For example, proband 1 is heteroallelic for C73R and A66V and has mild disease, as might be expected since the latter mutation expressed about 15% of normal activity in E. coli (Table IV) . Thus, the presence ofthe A66V allele provided sufficient URO-synthase activity to attenuate the severe transfusion-dependent phenotype of patients homozygous for the C73R allele. Heteroallelism for C73R and P53L also resulted in a severe phenotype (15), indicating that the P53L allele encodes an altered protein with little, if any, enzymatic activity, consistent with the results ofthe prokaryotic expression studies (Table IV) . Ofinterest, proband 2, who was heteroallelic for the C73R and T228M mutations, had moderately severe disease. Although prokaryotic expression of the T228M allele resulted in no detectable enzymatic activity, the fact that the proband was not transfusion-dependent, suggested that the T228M allele may produce active enzyme, albeit at very low levels. The threonine replacement may result in improper folding and/or instability of the mutant monomer. Since all CEP patients must synthesize heme, most non-consanguineous CEP patients should have at least one leaky mutation that expresses sufficient URO-synthase activity to maintain the minimal level of heme biosynthesis required for life. The amount of residual activity would determine the severity of the phenotype. This is consistent with the fact that disease severity in many inherited metabolic diseases is markedly altered by the presence of very low amounts ofresidual enzymatic activity (e.g., 28, 29) . Thus, the mutations causing CEP are heterogeneous, and those which express residual enzymatic activity lead to milder phenotypes even when the allelic mutation produces no enzymatic activity.
In summary, these studies identified four missense mutations causing CEP, designated T62A, A66V, C73R and T228M. Expression of these mutant alleles permitted an in vitro assessment oftheir ability to produce active enzyme, and thereby modify disease severity. The identification and expression of these mutations should permit molecular heterozygote detection, accurate genetic counseling, and improved prenatal diagnosis for CEP families with these lesions, as well as facilitate genotype-phenotype correlations for this inherited porphyria.
